ALLYRNA is a biotech company focusing on the R&D of innovative small-molecule drugs. With the development of first-in-class drugs as its core strategy, the company focuses on the field of oncology therapy and has established a unique technology platform for radiotherapy and immunotherapy sensitizers. Currently, the company's product pipeline covers multiple indications of high-incidence malignant tumors, including small cell lung cancer, rectal cancer, leukemia, pancreatic cancer and other disease areas with urgent clinical needs.

Regarding this round of financing, Professor Chuan He, Founder of ALLYRNA, stated: "The successful completion of this seed round financing marks an important milestone in the company's development. The financing funds will strongly promote the R&D breakthroughs and industrialization process of ALLYRNA's core pipeline. More importantly, it reflects that the capital market still highly recognizes our adherence to the first-in-class drug R&D strategy. It is particularly worth mentioning that TTM Capital, as a strategic partner, has deeply participated in the entire process of the company's establishment. TTM Capital has provided comprehensive professional support from company registration, core team building to R&D platform construction. We sincerely thank TTM Capital and other investors for their firm trust and continuous empowerment to ALLYRNA."

LILY ZHANG, Founding and Managing Partner of TTM Capital, said: "Professor Chuan He is a distinguished leading scientist in the field of chemical biology. His series of pioneering researches have laid an important scientific foundation for ALLYRNA's strategic R&D direction. As the co-lead investor of this round, we firmly believe that under the outstanding leadership of Professor Chuan He, ALLYRNA will surely develop new drug products with global competitiveness, strong innovation and significant clinical value, bringing transformative breakthroughs to oncology therapy."

Professor Chuan He

Professor Chuan He is a preeminent leading scientist in the field of chemical biology, currently serving as the John T. Wilson Distinguished Service Professor at the University of Chicago and a researcher at the Howard Hughes Medical Institute. As a global leader in the field of epitranscriptomics, his research has not only revealed the dynamic mysteries of RNA modifications but also opened up new pathology such as cancer research, neurobiology and genomic medicine. He was awarded the Wolf Prize in Chemistry 2023 for his pioneering contributions to the discovery and elucidation of the mechanism of reversible RNA methylation in the regulation of gene expression. In April 2024, he was elected as a member of the American Academy of Arts and Sciences in recognition of his outstanding contributions in the fields of biochemistry, molecular biology and genetics. Professor Chuan He obtained his Ph.D. from the Massachusetts Institute of Technology (MIT) and completed his postdoctoral research at Harvard University.

Who we are

TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies.
TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.